Výsledky vyhledávání - "Sumanta Monty Pal"

Evaluation of eligibility criteria in advanced prostate cancer clinical trials based on ASCO-FCR recommendations

Publikováno v: Journal of Clinical Oncology. 41:34-34

34 Background: The American Society of Clinical Oncology (ASCO) and the Friends of Cancer Research (FCR) published a joint statement addressing clinical eligibility for characteristics lacking adequate representation in recent studies (Kim et al., Cl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b3030884ce296068cb6b4d307ed0a45a
https://doi.org/10.1200/jco.2023.41.6_suppl.34

Zobrazit plný text záznamu

Antitumor immunity as the basis for durable disease-free, treatment-free survival (DDFTFS) in patients with metastatic urothelial cancer (mUC)

Autor: Jonathan Forrest Anker, Sumanta Monty Pal, Seunghee Kim-Schulze, Huan Wang, Rebecca Halperin, Andrew Uzilov, Takuro Saito, Noah M. Hahn, Manishkumar Patel, Jingjing Qi, Hui Xie, Nina Bhardwaj, Sacha Gnjatic, Matt D. Galsky

Publikováno v: Journal of Clinical Oncology. 41:536-536

536 Background: Cisplatin-based chemotherapy has been associated with functional cures (i.e., DDFTFS) in a small subset of patients with mUC. However, the mechanistic basis for this phenomenon has remained elusive. Immune checkpoint blockade may enha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::45b4859281e723d50c536362c1612e55
https://doi.org/10.1200/jco.2023.41.6_suppl.536

Zobrazit plný text záznamu

Phase 3 LITESPARK-022: Pembrolizumab (pembro) plus hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan as adjuvant treatment for clear cell renal cell carcinoma (ccRCC)

Autor: Toni K. Choueiri, Jens Bedke, Jose A. Karam, Rana R. McKay, Robert J. Motzer, Sumanta Monty Pal, Cristina Suárez, Robert Uzzo, Hong Liu, Joseph E. Burgents, Manish Sharma, Thomas Powles

Publikováno v: Journal of Clinical Oncology. 41:TPS748-TPS748

TPS748 Background: Treatment with the PD-1 inhibitor pembro produced significant improvement in disease-free survival after surgery for patients (pts) with ccRCC in the phase 3 KEYNOTE-564 trial. Based on these results, pembro was approved by the US

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9707aa3e1b330c1d24cc539ec4abd198
https://doi.org/10.1200/jco.2023.41.6_suppl.tps748

Zobrazit plný text záznamu

Impact of race and payor status on patterns of utilization of partial and radical nephrectomy in patients with localized renal cell carcinoma (RCC)

Autor: Regina Barragan-Carrillo, Kai Dallas, Abhishek Tripathi, Ameish Govindarajan, Zeynep Busra Zengin, Luis A Meza, Errol James Philip, Daniela V. Castro, Alexander Chehrazi-Raffle, Neal Chawla, Joann Hsu, Nazli Dizman, Karyn Eilber, Cristiane Decat Bergerot, Sumanta Monty Pal

Publikováno v: Journal of Clinical Oncology. 41:614-614

614 Background: Racial minorities experience intersecting forms of marginalization and suffer significant healthcare disparities. Prospective trials have shown similar outcomes with partial and radical nephrectomy among patients with localized RCC (V

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6f76207f8531f2832d4e684047ed4469
https://doi.org/10.1200/jco.2023.41.6_suppl.614

Zobrazit plný text záznamu

Evaluation of eligibility criteria in contemporary renal cell carcinoma based on ASCO-FCR recommendations

Publikováno v: Journal of Clinical Oncology. 41:612-612

612 Background: A consensus statement from the American Society of Clinical Oncology (ASCO) and Friends of Cancer Research (FCR) collaboration highlights the importance of expanding eligibility criteria in cancer trials to more accurately reflect the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9fe17a62ae245bda05c807fcb788d04a
https://doi.org/10.1200/jco.2023.41.6_suppl.612

Zobrazit plný text záznamu

Prevalence of dietary modification and supplement use in patients with metastatic renal cell carcinoma (mRCC)

Autor: Hedyeh Ebrahimi, Dena Battle, Zeynep Busra Zengin, Nazli Dizman, Luis A Meza, Daniela V. Castro, Ameish Govindarajan, Benjamin D. Mercier, Neal Shiv Chawla, Alex Chehrazi-Raffle, Abhishek Tripathi, Sandy Liu, Ulka N. Vaishampayan, Michael D. Staehler, Sumanta Monty Pal

Publikováno v: Journal of Clinical Oncology. 41:662-662

662 Background: Mounting data suggests that dietary modification and supplement use, including probiotics, may modulate outcomes with immunotherapy in cancer therapy (Spencer CN et al. Science 2021; Dizman N et al. Nature Medicine 2022). For the firs

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dff574e69ca7e1eba4d25a689bd05383
https://doi.org/10.1200/jco.2023.41.6_suppl.662

Zobrazit plný text záznamu

Optimal treatment by invoking biologic clusters in renal cell carcinoma (OPTIC RCC)

Autor: Yu-Wei Chen, Katy Beckermann, Scott Mattox Haake, Anupama Reddy, Yu Shyr, Michael B. Atkins, Nataliya Mar, Moshe Chaim Ornstein, Sumanta Monty Pal, Tian Zhang, Wendy Kimryn Rathmell, Brian I. Rini

Publikováno v: Journal of Clinical Oncology. 41:TPS742-TPS742

TPS742 Background: The first-line treatment for metastatic clear cell renal cell carcinoma (mccRCC) includes an immuno-oncology (IO) based combination. The current standard regimens include a PD-1 inhibitor plus either (1) an anti-CTLA-4 inhibitor (I

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4dc3beb60c795edb3799aecb1e739733
https://doi.org/10.1200/jco.2023.41.6_suppl.tps742

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání